Keros Therapeutics Inc

Important metrics include cash and short-term investments, total assets, current assets, total liabilities, current liabilities, long-term debt, shareholders' equity, retained earnings, inventory, receivables, working capital, current ratio, quick ratio, debt-to-equity ratio, and return on equity. Investors usually review these together rather than relying on one number.

Assets are resources the company owns or controls, such as cash, receivables, inventory, investments, and property. Liabilities are obligations the company owes, such as accounts payable, debt, leases, and taxes. Shareholders' equity is the residual value after liabilities are subtracted from assets.

Current assets and current liabilities are generally expected to be converted, used, paid, or settled within one year or one operating cycle. Non-current assets and non-current liabilities are longer-term items, such as property, long-term investments, deferred tax assets, long-term debt, and lease obligations.

In its most recent quarterly, Keros Therapeutics Inc had 281.50M in cash and cash equivalents.

Keros Therapeutics Inc reported 34.89M in total liabilities as of the latest reported quarter, including 20.41M in current liabilities and 14.47M in non-current liabilities.

As of the latest reported quarter, Keros Therapeutics Inc's total assets were 338.02M, consisting of 315.43M in current assets and 22.59M in non-current assets.

Keros Therapeutics Inc reported 303.13M in total shareholders' equity as of the latest reported quarter.